Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Clinical Outlook
  • Published:

Immunotherapy advances in cancers with mismatch repair or proofreading deficiencies

Nature Cancer volume 3, pages 1414–1417 (2022)Cite this article

Subjects

Tumors with DNA mismatch repair or proofreading deficiencies, either at the germinal or somatic level, usually present with high tumor mutational burden and often show striking responses to checkpoint blockade immunotherapy. Ongoing translational and clinical investigations of those tumor subsets provide avenues for further improvement in patient outcomes.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: MMRd and POLE-mutated tumors display high TMB and sensitivity to immunotherapy.

References

  1. Overman, M. J. et al. J. Clin. Oncol. 40, 3510 (2022).

    Article  Google Scholar 

  2. Chalabi, M. et al. Nat. Med. 26, 566–576 (2020).

    Article  CAS  Google Scholar 

  3. Chalabi, M. et al. Ann. Oncol. 33, S1389 (2022).

    Article  Google Scholar 

  4. Cercek, A. et al. N. Engl. J. Med. 386, 2363–2376 (2022).

    Article  CAS  Google Scholar 

  5. Diaz, L. A. et al. Lancet Oncol. 23, 659–670 (2022).

    Article  CAS  Google Scholar 

  6. Cohen, R. et al. JAMA Oncol. 5, 551–555 (2019).

    Article  Google Scholar 

  7. Chakrabarti, S. et al. J. Immunother. Cancer 10, e004485 (2022).

    Article  Google Scholar 

  8. Wang, Z. et al. J. Immunother. Cancer 10, e004703 (2022).

    Article  Google Scholar 

  9. Wang, Z. et al. BMC Med. 20, 133 (2022).

    Article  CAS  Google Scholar 

  10. Zhang, C. et al. J. Immunother. 45, 187–193 (2022).

    Article  CAS  Google Scholar 

  11. Chida, K. et al. Clin. Cancer Res. 28, 2110–2117 (2022).

    Article  CAS  Google Scholar 

  12. Nebot-Bral, L. et al. J. Immunother. Cancer. 10, e005059 (2022).

    Article  Google Scholar 

  13. Rousseau, B. et al. Cancer Discov. 12, 1435–1448 (2022).

    Article  CAS  Google Scholar 

  14. Graf, R. P. et al. JAMA Netw. Open 5, e225394 (2022).

    Article  Google Scholar 

  15. Crisafulli, G. et al. Cancer Discov. 12, 1656–1675 (2022).

    Article  Google Scholar 

Download references

Acknowledgements

B.R. is supported by Swim Across America and Memorial Sloan Kettering Cancer Center core grant MSKCC T32‐CA009512.

Author information

Authors and Affiliations

  1. Digestive Medical Oncology Department, IUCT-Rangueil, Toulouse Hospital University, Toulouse, France

    Emily Alouani

  2. Department of Medicine, Division of Solid Tumors, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Benoit Rousseau

  3. Sorbonne University, Department of Medical Oncology, Saint-Antoine Hospital, AP-HP, INSERM 938, SIRIC CURAMUS, Paris, France

    Thierry Andre

  4. Université Paris Saclay, Gustave Roussy, Departement d’Innovation Therapeutique et d’Essais Precoces (DITEP), INSERM U1015 & CIC1428, Villejuif, France

    Aurelien Marabelle

Authors
  1. Emily Alouani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Benoit Rousseau
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Thierry Andre
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Aurelien Marabelle
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aurelien Marabelle.

Ethics declarations

Competing interests

The authors have participated in clinical trials sponsored by Merck Sharp & Dohme, GlaxoSmithKline and Bristol Myers Squibb in the context of patients with MMRd and/or POLE-mutated tumors. Over the past five years, T.A. and A.M. have participated in compensated scientific advisory boards from Merck Sharp & Dohme, GlaxoSmithKline and Bristol Myers Squibb.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Alouani, E., Rousseau, B., Andre, T. et al. Immunotherapy advances in cancers with mismatch repair or proofreading deficiencies. Nat Cancer 3, 1414–1417 (2022). https://doi.org/10.1038/s43018-022-00497-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s43018-022-00497-5

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer